Covira Surgical
North Chicago
About Covira Surgical
Covira Surgical engages in the development of drugs that modulate the biological activity of the gut microbiome's resident bacteria. It is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira’s platform technology generated a lead asset (CS-0003) that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. Covira’s approach is transformative to the field and the world is taking notice...in the 4th quarter of last year, Business Worldwide Magazine named Covira Among the 2021 - Top 20 Most Innovative Companies to Watch.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $11.1M
- Funding stage: Seed
- Last round: Grant (Oct 2022)
- Website: covirasurgical.com
Industries & Categories
Biopharma, Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/covira-surgical-74880 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.